Ueno Hiroaki, Nakazato Hiroko, Ebihara Emi, Noma Kenji, Kawano Takahisa, Nagamine Kazuhiro, Sakoda Hideyuki, Nakazato Masamitsu
Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Noma Naika Clinic, Miyazaki, Japan.
Diabetes Ther. 2018 Feb;9(1):403-411. doi: 10.1007/s13300-018-0366-8. Epub 2018 Jan 10.
Ipragliflozin is a novel antidiabetic drug that inhibits renal tubular sodium-glucose cotransporter-2 (SGLT2). The aim of this study was to evaluate the effects of ipragliflozin on glucose, insulin, glucagon, and gastrointestinal peptide responses to a meal tolerance test, as well as to investigate the glucose-lowering mechanisms of ipragliflozin.
Nine Japanese patients with obesity and type 2 diabetes mellitus were treated with ipragliflozin (50 mg/day) for 12 weeks. The postprandial profiles of glucose, insulin, glucagon, active glucagon-like peptide-1 (GLP-1), active glucose-dependent insulinotropic polypeptide (GIP), ghrelin, and des-acyl ghrelin were measured before and 12 weeks after ipragliflozin treatment.
Body weight, body fat mass, systolic blood pressure, and HbA1c and serum uric acid levels were significantly decreased after the treatment. Postprandial glucose and insulin levels were also significantly decreased. Postprandial glucagon increased both before and after ipragliflozin treatment; however, the increment tended to be smaller after treatment. Active GLP-1, active GIP, ghrelin, and des-acyl ghrelin did not change after treatment.
Ipragliflozin improved glycemic control by reducing body weight, postprandial inappropriate glucagon secretion, and the postprandial insulin requirement. Although this was a short-term study with a small sample size, ipragliflozin may offer benefits for patients with obesity and type 2 diabetes mellitus.
University Hospital Medical Information Network (UMIN No. 000017195).
依帕列净是一种新型抗糖尿病药物，可抑制肾小管钠-葡萄糖协同转运蛋白2（SGLT2）。本研究旨在评估依帕列净对糖耐量试验中血糖、胰岛素、胰高血糖素和胃肠肽反应的影响，并探讨依帕列净的降糖机制。
9名日本肥胖2型糖尿病患者接受依帕列净（50毫克/天）治疗12周。在依帕列净治疗前和治疗12周后，测量葡萄糖、胰岛素、胰高血糖素、活性胰高血糖素样肽-1（GLP-1）、活性葡萄糖依赖性促胰岛素多肽（GIP）、胃饥饿素和去酰基胃饥饿素的餐后变化情况。
治疗后体重、体脂量、收缩压、糖化血红蛋白（HbA1c）和血清尿酸水平显著降低。餐后血糖和胰岛素水平也显著降低。依帕列净治疗前后餐后胰高血糖素均升高；然而，治疗后升高幅度趋于减小。治疗后活性GLP-1、活性GIP、胃饥饿素和去酰基胃饥饿素未发生变化。
依帕列净通过减轻体重、餐后不适当的胰高血糖素分泌和餐后胰岛素需求改善血糖控制。尽管这是一项样本量较小的短期研究，但依帕列净可能对肥胖2型糖尿病患者有益。
大学医院医学信息网络（UMIN编号：000017195）。
